CombiMatrix received an initial $1 million upfront payment in May of this year from Toppan when the alliance was formed.
Amit Kumar, Ph.D., President and Chief Executive Officer of CombiMatrix, commented, “We are working with Toppan to develop a microarray product suite based on our proprietary electrochemical detection approach. This approach should enable smaller and less expensive detection instrumentation and potential improvement of performance characteristics over conventional microarrays, which use optical methods for detection. The first application of these microarrays may be for biological and chemical warfare agent detection followed by broader life science applications.”
Under the terms of the agreement, CombiMatrix and Toppan are co-developing semiconductor microarrays for applications in life science research, biological and chemical warfare agent detection, as well as diagnostics.
Upon commercialization, Toppan will manufacture microarrays for CombiMatrix or its partners and will share revenues and royalties on these products.
Acacia Research Corporation comprises two operating groups, Acacia Technologies Group and CombiMatrix Group.
The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins.
CombiMatrix’ technology has a wide range of applications including DNA synthesis/diagnostics, siRNA synthesis, drug discovery, and immunochemical detection.
CombiMatrix provides DNA arrays to researchers under the CustomArray (TM) brand.
The Acacia Technologies group licenses its Digital Media Transmission (DMT) technology to media and electronics companies.
The DMT technology covers the transmission and receipt of digital audio and digital video content, commonly known as audio on-demand, video on-demand, and audio/video streaming, and is supported by 5 U.S. and 17 international patents.